Pharmaceuticals

Manufacture and sales of a wide range of pharmaceuticals,

  • Okayama Plant

Focus on neuropsychiatric and allergic disorders

  • Focus on neuropsychiatric and allergic disorders
  • Focus on neuropsychiatric and allergic disorders

For many years, we have manufactured and sold a variety of pharmaceutical products, such as anti depressants widely used in the medical field, sleep disorder treatment drugs that are designated as orphan drugs , and allergic disease treatments that demonstrate superior clinical efficacy in treating allergic symptoms such as urticaria and bronchial asthma. We also have a therapeutic drug which accelerates the metabolism of tri glycerides for the treatment of liver diseases.In addition, we are working actively to create new drugs including"Midafressa," an anti convulsant launched in December 2014 as a new option for treating status epilepticus; and "Vigabatrin," a jointly developed anti epilepsy drug.

New drug development of drugs already approved overseas for the domestic market

  • New drug development of drugs already approved overseas for the domestic market

We are promoting initiatives for the domestic launch of drugs that have been approved for valid treatment overseas in response to cases in which a disease has no treatment or its treatment satisfaction is low. One of these, called Choreazine, is for the treatment of chorea associated with Huntington's disease. Alfresa Pharma obtained the manufacturing and marketing approval of Choreazine in December 2012 for the first time for the treatment of the afore mentioned disorder. Choreazine has already been approved and is sold in many countries worldwide.

Home

Company Information

Business Domain

  • Business Domain Index
  • International Business
  • API Business
  • Pharmaceuticals
  • Diagnostic Regents
  • Medical Devices & Equipment
  • Contract Manufacturing
  • Contract Manufacturing
  • alfresa Alfresa Holdings Corporation
  • alfresa group